Free Trial

HC Wainwright Has Bearish Forecast for INO FY2026 Earnings

Inovio Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2026 EPS forecast for Inovio Pharmaceuticals to a loss of $0.98 per share from a projected loss of $0.73, while maintaining a Buy rating and $5 price target.
  • Analysts’ overall view remains a Moderate Buy, with a consensus price target of $6.33; ratings include four Buys, one Hold, and one Sell.
  • Inovio’s latest quarterly results missed expectations: it reported a $0.50-per-share loss and $0.30 million in revenue, versus estimates of a $0.21-per-share loss and $2.27 million in revenue.
  • MarketBeat previews top five stocks to own in December.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - HC Wainwright lowered their FY2026 earnings per share estimates for Inovio Pharmaceuticals in a research report issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($0.98) for the year, down from their prior estimate of ($0.73). HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Inovio Pharmaceuticals' current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.11 EPS, Q4 2027 earnings at $0.20 EPS and FY2027 earnings at $0.18 EPS.

A number of other analysts have also commented on INO. Zacks Research downgraded shares of Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, October 12th. Wall Street Zen raised shares of Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Inovio Pharmaceuticals in a report on Wednesday. Piper Sandler reissued an "overweight" rating and set a $6.00 target price (down from $8.00) on shares of Inovio Pharmaceuticals in a research report on Wednesday, November 11th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $8.00 target price (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 6th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Inovio Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $6.33.

View Our Latest Report on Inovio Pharmaceuticals

Inovio Pharmaceuticals Stock Performance

NASDAQ INO opened at $1.43 on Monday. The company has a fifty day simple moving average of $1.18 and a 200 day simple moving average of $1.27. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.72. The company has a market cap of $157.56 million, a P/E ratio of -2.65 and a beta of 1.71.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.29). The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $2.27 million.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several large investors have recently bought and sold shares of INO. Marshall Wace LLP bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter worth $2,780,000. Eversept Partners LP purchased a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at about $1,802,000. Renaissance Technologies LLC lifted its position in shares of Inovio Pharmaceuticals by 16.4% during the first quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company's stock valued at $1,120,000 after purchasing an additional 90,613 shares in the last quarter. Green Alpha Advisors LLC lifted its position in shares of Inovio Pharmaceuticals by 68.8% during the third quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company's stock valued at $140,000 after purchasing an additional 46,802 shares in the last quarter. Finally, LexAurum Advisors LLC purchased a new position in Inovio Pharmaceuticals during the third quarter worth about $118,000. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Company Profile

(Get Free Report)

Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body's immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company's technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.

Featured Stories

Earnings History and Estimates for Inovio Pharmaceuticals (NASDAQ:INO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?

Before you consider Inovio Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.

While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines